openPR Logo
Press release

HIV Market by Diagnostics and Therapeutics 2018 by Companies Profiles (Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers, Thermo Fisher Scientific) and Forecast Till 2023

10-29-2018 12:23 PM CET | Health & Medicine

Press release from: Orbis Research

HIV Market by Diagnostics and Therapeutics 2018 by Companies Profiles (Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., Glax

HIV Market by Diagnostics and Therapeutics 2018 by Companies Profiles (Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., Glax

HIV Diagnostics and Therapeutics Market (Human immunodeficiency virus) 2018-2023:
The global HIV therapeutics market was valued at REDACTED in 2017 and is estimated to reach REDACTED in 2023, growing at a CAGR of REDACTED over the forecast period (2018–2023). As of 2018, the single-tablet regimen FDC segment holds REDACTED of the market share of the global HIV therapeutics market, as this has become the preferred therapy for HIV treatment due to increased patient compliance. As fixed-dose combinations reduce dosing errors and lower the likelihood of the HIV virus becoming drug resistant, they are increasingly preferred. By 2023, NRTIs will hold REDACTED of the global market, a REDACTED value, as they form the backbone o f any antiretroviral therapy.

Download a PDF Sample of this Report @ http://www.orbisresearch.com/contacts/request-sample/2359080#utm_source=shreyas

HIV is a sexually transmitted disease that develops rapidly and spreads widely if adequate prevention is not implemented. HIV is prevalent around the globe, with an estimated 36.9 million people living with the disease worldwide in 2017 and 1.8 million new infections in 2017 year alone, as reported by the Joint United Nations Programme on HIV and AIDS. There is effective antiretroviral treatment available for the management of the disease, and treatment coverage has been extended to developing nations. In the absence of an effective treatment that cures the disease, governments are relying on HIV diagnostics and prevention methods to slow the spread of this epidemic.

The disease is transmitted through the exchange of body fluids, which can occur through sexual encounters and contaminated blood or blood products. It can also be transmitted from a pregnant woman to her infant during pregnancy, delivery or breast-feeding. It has also been reported that transmission can occur from organ transplants if the donor is HIV-positive. HIV is highly divergent, and there are several subtypes that exist globally. The two major HIV subtypes are HIV-1 and HIV-2. HIV testing is conducted to ensure the safety of blood, blood products and organ transplantation, as well as patient diagnosis.

For effective HIV management, the key strategies are early diagnosis, rapid antiretroviral therapy (ART) initiation and viral load monitoring. A key issue with existing HIV therapies is that they fail to address two rising concerns: the long-term adverse effects of therapeutic drugs and effectiveness against drugresistant HIV strains.

Enquiry before buying report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2359080

This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR during the forecast period. Market data in terms of value is provided at global, regional and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class and discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase stand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

Market dynamics, such as trends and challenges, are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. The regional overviews provide information on the epidemiology of HIV by country and region and details market data for each region. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to readers of this report. The pipeline analysis chapter discusses four major drug categories to provide details on major pipeline developments. The competitive landscape discusses the major manufacturers involved in the HIV therapeutics market, key developments and product offerings.

Report Includes:

- 37 data tables and 49 additional tables
- Industry analysis of diagnostics and therapeutics for the HIV disease, and its global markets
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Characterization and quantification of market potential for therapeutic drugs for HIV virus by drug categories, diagnostic test types, application sectors and geographical regions
- Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
- Evaluation of the market dynamics such as drivers, restraints and current industry trends and patterns
- Discussion of the regulatory scenario for United States, Europe, and Japan to provide an overview of the regulations for new drug launches and diagnostic kits
- Examination of cost implications for treatments across a range of countries
- A look at ongoing research and the future direction of the market
- Assessment of the competitive landscape and discussion of the major manufacturers involved in the HIV therapeutics market, key developments and product offerings, including Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific

Download Free PDF Sample: http://www.orbisresearch.com/contacts/request-sample/2359080#utm_source=shreyas

Companies Mentioned:
• ABBOTT LABORATORIES
• ABBVIE INC.
• AGILENT TECHNOLOGIES INC.
• AUROBINDO PHARMA LTD.
• BECTON, DICKINSON AND CO.
• BIO-RAD LABORATORIES INC.
• BRISTOL-MYERS SQUIBB CO.
• CEPHEID INC.
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• HOFFMANN-LA ROCHE INC.
• HOLOGIC INC.
• JANSSEN PHARMACEUTICALS INC.
• MERCK & CO. INC.
• MERIDIAN LIFE SCIENCE INC.
• SIEMENS HEALTHINEERS
• THERMO FISHER SCIENTIFIC INC.
• VIIV HEALTHCARE

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Overview of Human Immunodeficiency Virus (HIV)
Report Overview
Disease Prognosis
Symptoms
Treatments
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Pre-exposure Prophylaxis (PrEP)
Post-exposure Prophylaxis (PEP)
Drug Resistance
Medication Adherence
WHO Initiatives
Chapter 4 Global Industry Trends
Trends in Global HIV Transmission
Regional Awareness Programs
Development of Novel Therapies
Public-Private Partnerships
Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
Global Programs to Counter HIV
Preventing Transmission from Mother to Child
Challenges
Underestimating the Risk of Contracting the Disease
Social Stigma Associated with STDs
High Cost of Treatment
Chapter 5 Global HIV Therapeutics Market
Global HIV Therapeutics Market and Forecast Overview
North American HIV Therapeutics Market
Epidemiology
HIV Testing and Recommendations
Regulations Impacting the North American HIV Therapeutics Market
Market Analysis and Forecast
European HIV Therapeutics Market
Epidemiology
HIV Testing and Recommendations
Regulations Impacting the European HIV Market
Market Analysis and Forecast
Asia-Pacific HIV Therapeutics Market
Epidemiology
Prevention and Screening Programs
Regulations Impacting the Asia-Pacific HIV Market
Market Impact of Generic Manufacturers
Market Analysis and Forecast
Rest of World (RoW) HIV Therapeutics Market
Epidemiology
Market Analysis and Forecast
Global Investments in HIV Market
Chapter 6 HIV Therapeutics Market by ARV Drug Categories
Timeline of Therapies
First-Line Treatment Regimen
Second-line Treatment Regimen
Third-line/Salvage Treatment Regimen
Market Overview by Drug Category
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitors (PIs)
Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
Integrase Strand Transfer Inhibitors (INSTI)
Non-nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
Entry Inhibitors
Chapter 7 Leading Drugs in the HIV Therapeutics Market
Leading HIV Drugs
Drug Profiles
Genvoya
Triumeq
Truvada
Tivicay (Dolutegravir)
Prezista/Prezcobix/Rezolsta/Symtuza
Atripla
Descovy
Isentress/Isentress HD
Odefsey
Stribild
Eviplera
Viread
Promising Emerging Therapies
Darunavir/Cobicistat/FTC/TAF Fixed-dose Combination
Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Ibalizumab (Trogarzo)
Estimated Drug Revenue Forecast
Genvoya
Triumeq and Tivicay
Odefsey
Stribild
Chapter 8 HIV Diagnostics Market
HIV Diagnostics Market by Test Type
Evolution of HIV Tests
Antigen- and Antibody-Based Tests
Future Perspective
CD4 Testing
Future Perspective
Viral Load Testing
Future Perspective
HIV Diagnostics Product Profiles by Test Type
CD4 Testing Products
Viral Load Testing Products
Chapter 9 Pipeline Analysis
HIV Pipeline Overview
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Drugs in Development
NNRTI Drugs in Development
Doravirine/TDF/3TC
Other Categories
Generic Dolutegravir (Integrase Inhibitors)
Albuvirtide (Aikening) (Fusion inhibitors)
Juluca (Dolutegravir/Rilpivirine)
Isentress HD (Raltegravir) (Integrase Inhibitors)
Combination Therapies
Approved and Tentatively Approved Antiretrovirals
Chapter 10 Regulatory and Reimbursement Structure
Overview of Regulations
United States
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
Chapter 11 Competitive Landscape and Key Developments
Market Share Analysis
Patent Analysis
Key Developments
Chapter 12 Company Profiles

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV Market by Diagnostics and Therapeutics 2018 by Companies Profiles (Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers, Thermo Fisher Scientific) and Forecast Till 2023 here

News-ID: 1335711 • Views:

More Releases from Orbis Research

Blood Purification Devices Market 2023-2028 | Top Players Baxter International, Cerus Corporation, Cytosorbents Corporation, Nikkiso Co.Ltd, Asahi Kasei Corporation, Aethlon Medical, Haemonetics, Jafron, B. Braun, Fresenius
Blood Purification Devices Market 2023-2028 | Top Players Baxter International, …
Based on the type segment, the portable equipment segment is expected to hold the largest share in Blood Purification Devices in the year 2028. Professionals that are actively involved in the ongoing purification of blood tend to favour portable equipment. Equipment that is portable enables effective emergency care. Additionally, portable equipment is rather space-efficient and compact, which promotes widespread use throughout the blood-purification process. In a manner similar to how
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Minerals, The Honest Company, Fenty Beauty, Aveda Corporation, Westman Atelier, Victoria Beckham Beauty, Kora Organics, Saie, and True Botanicals
Clean Beauty Market to Grow at 40.1% CAGR by 2028 - Key Players are Bare Mineral …
Clean beauty is described as beauty and personal care products that are made with the safest possible ingredients and have the lowest possible environmental impacts. Clean beauty pertains to products that are safe, non-toxic, and clearly labelled ingredients Also, the ingredients used are cruelty-free and are screened for non-GMO feedstock and residual pesticides. Request a pdf brochure @ https://www.orbisresearch.com/contacts/request-sample/6941781 The Clean Beauty Market is valued at USD 5163.17 Million in 2021 and
Outdoor Power Equipment Market Worth USD 6.49 Bn by 2027 - Industry Trends and S …
The outdoor power equipment generally includes, brush cutters, edger, chain saws, power rakes, and more. Outdoor power equipment is commonly used by end users, such as lawn & plant care providers and landscape service providers, for commercial purposes. The global outdoor power equipment market in 2021 was valued at US$32.22 billion. The market value is projected to reach US$46.49 billion by 2027. Outdoor power equipment (OPE) is an equipment with small
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth Drivers, Key Companies and Future Opprtunities
Merchant API Market to reach US$119.11 billion by 2027 - Industry Trends, Growth …
The latest research on "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By End-User, By Region Size And Trends With Impact Of COVID-19 And Forecast up to 2027" have been added to OrbisResearch.com store. The merchant API market refers to the use of APIs by merchants, or businesses that sell goods and services, to connect their systems and processes with those of other

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral